Apogee Therapeutics, Inc.
DelistedCIK 1974640fmd_11PDVX58GM64PD4W8PV93X3K49Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Apr 01, 2022 to Jun 30, 2026, 16 periods
Latest annual · FY2025
Millions- Operating income
- (286)
- Net income
- (256)
- Free cash flow
- (233)
Latest quarter · Q2 FY2026
Millions- Operating income
- (96)
- Net income
- (86)
Apogee Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$285.6 million | -$216.9 million | 10-K 2026-03-02 · proof | |
| Net income | -$255.8 million | -$182.1 million | 10-K 2026-03-02 · proof | |
| Cash from operating activities | -$227.5 million | -$171.2 million | 10-K 2026-03-02 · proof | |
| Free cash flow | -$232.6 million | -$172.3 million | 10-K 2026-03-02 · proof | |
| Total assets | $937.1 million | $754 million | +24.3% | 10-K 2026-03-02 · proof |
| Total liabilities | $33.3 million | $37.2 million | -10.5% | 10-K 2026-03-02 · proof |
| Cash and cash equivalents | $131.5 million | $141.8 million | -7.2% | 10-K 2026-03-02 · proof |
- What was Apogee Therapeutics, Inc.'s operating income in fiscal 2025?
- Apogee Therapeutics, Inc. reported operating income of -$285.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$216.9 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What was Apogee Therapeutics, Inc.'s net income in fiscal 2025?
- Apogee Therapeutics, Inc. reported net income of -$255.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$182.1 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What was Apogee Therapeutics, Inc.'s cash from operating activities in fiscal 2025?
- Apogee Therapeutics, Inc. reported cash from operating activities of -$227.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$171.2 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What was Apogee Therapeutics, Inc.'s free cash flow in fiscal 2025?
- Apogee Therapeutics, Inc. reported free cash flow of -$232.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$172.3 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What are Apogee Therapeutics, Inc.'s total assets?
- As of Dec 31, 2025, Apogee Therapeutics, Inc. reported total assets of $937.1 million, against $754 million a year earlier (+24.3%). Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What are Apogee Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2025, Apogee Therapeutics, Inc. reported total liabilities of $33.3 million, against $37.2 million a year earlier (-10.5%). Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What are Apogee Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2025, Apogee Therapeutics, Inc. reported cash and cash equivalents of $131.5 million, against $141.8 million a year earlier (-7.2%). Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1974640&period_type=annual&limit=5"Information only, not investment advice.